Patient-reported outcomes and work productivity were more negatively affected by hepatitis C treatment regimens that included pegylated interferon compared with interferon-free regimens, according to recent study data.
Zobair Younossi, MD, of the Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Virginia, and colleagues evaluated the patient-reported outcomes (PROs) obtained from questionnaires completed during two recent phase 3 clinical trials of sofosbuvir-based treatments with and without interferon. The FUSION study included 201 patients infected with HCV who received sofosbuvir and ribavirin for 12 or 16 weeks. The NEUTRINO study included 327 patients infected with HCV who received sofosbuvir and ribavirin plus interferon for 12 weeks.
“Our data have suggested the superiority of interferon-free regimen from
a patient-related outcome standpoint,” the researchers concluded. “In
addition, we have shown that fatigue was the most important driver of
these patient outcomes before treatment and during treatment. Finally,
achievement of SVR 12 weeks after treatment had not only clinical
benefits but also PRO benefits. These data can be used to provide a more
comprehensive assessment of a treatment regimen that not only includes
efficacy and safety but also patients’ experiences derived through PRO